CEREUnknown
Cerevel Therapeutics Holdings, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Cerevel Therapeutics Holdings, Inc. (CERE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are CERE insiders buying or selling?
Cerevel Therapeutics Holdings, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since October 2020, Trabud has recorded 70 Form 4 filings for CERE: 18 buys ($799.8M) and 52 sells ($60.7M).
Source: SEC EDGAR Form 4
Key Statistics (October 2020 – Jul 3, 2024)
Total Form 4 filings
70
SEC EDGAR
Insider filers
17
Insider buys (18)
$799.8M
Insider sells (52)
$60.7M
Insider sentiment
Net buyingNet insider flow of $739.1M in net buying since October 2020.
Recent CERE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 3, 2024 | Anthony N Coles | Director | Sale | 25.0K | $41.18 | $1.0M | SEC ↗ |
| Jun 5, 2024 | Anthony N Coles | Director | Sale | 50.0K | $40.61 | $2.0M | SEC ↗ |
| May 14, 2024 | Anthony N Coles | Director | Sale | 50.0K | $42.10 | $2.1M | SEC ↗ |
| Apr 3, 2024 | Anthony N Coles | Director | Sale | 50.0K | $42.33 | $2.1M | SEC ↗ |
| Mar 6, 2024 | Anthony N Coles | Director | Sale | 50.0K | $41.01 | $2.1M | SEC ↗ |
| Mar 4, 2024 | Anthony N Coles | Director | Sale | 50.0K | $41.16 | $2.1M | SEC ↗ |
| Feb 9, 2024 | John Renger | Chief Scientific Officer | Sale | 2.2K | $41.54 | $89.8K | SEC ↗ |
| Feb 9, 2024 | Anthony N Coles | Director | Sale | 2.5K | $41.54 | $104.1K | SEC ↗ |
| Jan 4, 2024 | Anthony N Coles | Director | Sale | 50.0K | $42.24 | $2.1M | SEC ↗ |
| Dec 28, 2023 | Ramiro Sanchez | Chief Medical Officer | Sale | 10.0K | $42.47 | $424.7K | SEC ↗ |
| Dec 27, 2023 | Kenneth Dipietro | Chief Human Resources Officer | Sale | 8.0K | $41.45 | $331.6K | SEC ↗ |
| Dec 22, 2023 | Ramiro Sanchez | Chief Medical Officer | Sale | 10.2K | $41.42 | $420.5K | SEC ↗ |
| Dec 22, 2023 | Kathleen Tregoning | Title: Chief Corporate Affairs Officer | Sale | 6.3K | $41.42 | $260.5K | SEC ↗ |
| Dec 19, 2023 | Ramiro Sanchez | Chief Medical Officer | Sale | 7.5K | $41.39 | $310.4K | SEC ↗ |
| Dec 11, 2023 | Ramiro Sanchez | Chief Medical Officer | Sale | 10.0K | $41.37 | $413.7K | SEC ↗ |
| Dec 8, 2023 | Scott Akamine | Chief Legal Officer | Sale | 17.5K | $38.64 | $676.2K | SEC ↗ |
| Nov 16, 2023 | Anthony N Coles | Director | Sale | 22.8K | $25.13 | $573.5K | SEC ↗ |
| Nov 9, 2023 | Anthony N Coles | Director | Sale | 27.2K | $25.02 | $680.1K | SEC ↗ |
| Nov 6, 2023 | Anthony N Coles | Director | Sale | 100.0K | $25.34 | $2.5M | SEC ↗ |
| Nov 3, 2023 | PATRICK DEVAL L | Director | Sale | 30.1K | $25.00 | $753.3K | SEC ↗ |
| Oct 18, 2023 | Christopher R Gordon | Director, 10% Owner | Purchase | 5.5M | $22.81 | $125.0M | SEC ↗ |
| Oct 18, 2023 | Adam Koppel | Director, 10% Owner | Purchase | 5.5M | $22.81 | $125.0M | SEC ↗ |
| Oct 18, 2023 | BAIN CAPITAL INVESTORS LLC | 10% Owner | Purchase | 5.5M | $22.81 | $125.0M | SEC ↗ |
| Oct 17, 2023 | Joseph Edelman | Director | Purchase | 876.8K | $22.81 | $20.0M | SEC ↗ |
| Sep 8, 2023 | Anthony N Coles | Director | Sale | 50.0K | $24.07 | $1.2M | SEC ↗ |
Showing the 25 most recent of 70 Form 4 filings for Cerevel Therapeutics Holdings, Inc..
Most active CERE insiders
- Anthony N Coles19 filings
- John Renger17 filings
- Joseph Edelman6 filings
- Abraham Ceesay4 filings
- Ramiro Sanchez4 filings
Ask anything about CERE insider activity
Use Trabud's AI agent to query Cerevel Therapeutics Holdings, Inc.'s Form 4 history in plain English — "Show me CERE CEO purchases this year" or compare it against any other ticker.
Open the AI agentCERE insider trading FAQ
Are Cerevel Therapeutics Holdings, Inc. insiders buying or selling?
Cerevel Therapeutics Holdings, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since October 2020, Trabud has recorded 70 Form 4 filings for CERE: 18 buys ($799.8M) and 52 sells ($60.7M). Over the full record that is net buying of $739.1M.
How many insiders trade CERE stock?
17 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Cerevel Therapeutics Holdings, Inc.. The most recent filing was accepted on Jul 3, 2024.
Where does Trabud get CERE insider trading data?
All CERE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.